Atibeprone is an antidepressant which was developed in the mid-1990s, but was never marketed.

Rolipram is a selective phosphodiesterase-4 inhibitor discovered and developed by Schering AG as a potential antidepressant drug in the early 1990s. Rolipram was discontinued after clinical trials showed that its therapeutic window was too narrow. Rolipram could not be dosed at high enough levels to be effective without causing significant gastrointestinal side effects. Rolipram promotes apoptosis in HL60 cells through a cAMP-independent mechanism and has been shown to enhance neuronal survival.

Insulin aspart, a human insulin analogue, is a rapid-acting, parenteral blood glucose-lowering agent. Insulin aspart was marketed under the brand name NovoLog for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. The primary activity of the drug is the regulation of glucose metabolism. Insulin aspart binds to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver. This drug has an off-label treatment for gestational diabetes (temporary diabetes caused by diabetes).